Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Matheson, David"'
Autor:
James, Nicholas D., Clarke, Noel W., Cook, Adrian, Ali, Adnan, Hoyle, Alex P., Attard, Gert, Brawley, Chris D., Chowdhury, Simon, Cross, William R., Dearnaley, David P., Bono, Johann S., Montana, Carlos Diaz, Gilbert, Duncan, Gillessen, Silke, Gilson, Clare, Jones, Rob J., Langley, Ruth E., Malik, Zafar I., Matheson, David J., Millman, Robin, Parker, Chris C., Pugh, Cheryl, Rush, Hannah, Russell, J. Martin, Berthold, Dominic R., Buckner, Michelle L., Mason, Malcolm D., Ritchie, Alastair W.S., Birtle, Alison J., Brock, Susannah J., Das, Prantik, Ford, Dan, Gale, Joanna, Grant, Warren, Gray, Emma K., Hoskin, Peter, Khan, Mohammad M., Manetta, Caroline, McPhail, Neil J., O'Sullivan, Joe M., Parikh, Omi, Perna, Carla, Pezaro, Carmel J., Protheroe, Andrew S., Robinson, Angus J., Rudman, Sarah M., Sheehan, Denise J., Srihari, Narayanan N., Syndikus, Isabel, Tanguay, Jacob, Thomas, Carys W., Vengalil, Salil, Wagstaff, John, Wylie, James P., Parmar, Mahesh K.B., Sydes, Matthew R.
Publikováno v:
James, N D, Clarke, N W, Cook, A, Ali, A, Hoyle, A P, Attard, G, Brawley, C D, Chowdhury, S, Cross, W R, Dearnaley, D P, Bono, J S, Montana, C D, Gilbert, D, Gillessen, S, Gilson, C, Jones, R J, Langley, R E, Malik, Z I, Matheson, D J, Millman, R, Parker, C C, Pugh, C, Rush, H, Russell, J M, Berthold, D R, Buckner, M L, Mason, M D, Ritchie, A WS, Birtle, A J, Brock, S J, Das, P, Ford, D, Gale, J, Grant, W, Gray, E K, Hoskin, P, Khan, M M, Manetta, C, McPhail, N J, O'Sullivan, J M, Parikh, O, Perna, C, Pezaro, C J, Protheroe, A S, Robinson, A J, Rudman, S M, Sheehan, D J, Srihari, N N, Syndikus, I, Tanguay, J, Thomas, C W, Vengalil, S, Wagstaff, J, Wylie, J P, Parmar, M KB & Sydes, M R 2022, ' Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476) ', International Journal of Cancer . https://doi.org/10.1002/ijc.34018
Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multi-arm, multi-stage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d41e4f972431efac3e44597e81d1a4a
https://pure.qub.ac.uk/en/publications/3adddebe-1d1a-4134-8495-5f087a1fee9e
https://pure.qub.ac.uk/en/publications/3adddebe-1d1a-4134-8495-5f087a1fee9e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Parker, Christopher C., James, Nicholas D., Brawley, Christopher D., Clarke, Noel W., Hoyle, Alex P., Ali, Adnan, Ritchie, Alastair W.S., Attard, Gerhardt, Chowdhury, Simon, Cross, William, Dearnaley, David P., Gillessen, Silke, Gilson, Clare, Jones, Robert J., Langley, Ruth E., Malik, Zafar I., Mason, Malcolm D., Matheson, David, Millman, Robin, Russell, J. Martin, Thalmann, George N., Amos, Claire L., Alonzi, Roberto, Bahl, Amit, Birtle, Alison, Din, Omar, Douis, Hassan, Eswar, Chinnamani, Gale, Joanna, Gannon, Melissa R., Jonnada, Sai, Khaksar, Sara, Lester, Jason F., O'Sullivan, Joe M., Parikh, Omi A., Pedley, Ian D., Pudney, Delia M., Sheehan, Denise J., Srihari, Narayanan Nair, Tran, Anna T.H., Parmar, Mahesh K.B., Sydes, Matthew R.
Publikováno v:
Parker, C C, James, N D, Brawley, C D, Clarke, N W, Hoyle, A P, Ali, A, Ritchie, A W S, Attard, G, Chowdhury, S, Cross, W, Dearnaley, D P, Gillessen, S, Gilson, C, Jones, R J, Langley, R E, Malik, Z I, Mason, M D, Matheson, D, Millman, R, Russell, J M, Thalmann, G N, Amos, C L, Alonzi, R, Bahl, A, Birtle, A, Din, O, Douis, H, Eswar, C, Gale, J, Gannon, M R, Jonnada, S, Khaksar, S, Lester, J F, O'sullivan, J M, Parikh, O A, Pedley, I D, Pudney, D M, Sheehan, D J, Srihari, N N, Tran, A T H, Parmar, M K B & Sydes, M R 2018, ' Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial ', The Lancet, vol. 392, no. 10162, pp. 2353-2366 . https://doi.org/10.1016/S0140-6736(18)32486-3
Lancet (London, England)
Parker, Christopher C; James, Nicholas D; Brawley, Christopher D; Clarke, Noel W; Hoyle, Alex P; Ali, Adnan; Ritchie, Alastair W S; Attard, Gerhardt; Chowdhury, Simon; Cross, William; Dearnaley, David P; Gillessen, Silke; Gilson, Clare; Jones, Robert J; Langley, Ruth E; Malik, Zafar I; Mason, Malcolm D; Matheson, David; Millman, Robin; Russell, J Martin; ... (2018). Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392(10162), pp. 2353-2366. Elsevier 10.1016/S0140-6736(18)32486-3
Lancet (London, England)
Parker, Christopher C; James, Nicholas D; Brawley, Christopher D; Clarke, Noel W; Hoyle, Alex P; Ali, Adnan; Ritchie, Alastair W S; Attard, Gerhardt; Chowdhury, Simon; Cross, William; Dearnaley, David P; Gillessen, Silke; Gilson, Clare; Jones, Robert J; Langley, Ruth E; Malik, Zafar I; Mason, Malcolm D; Matheson, David; Millman, Robin; Russell, J Martin; ... (2018). Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392(10162), pp. 2353-2366. Elsevier 10.1016/S0140-6736(18)32486-3
BACKGROUND Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::996a38e0fa5edd02ec02b4d7ea6fca6c
https://research.manchester.ac.uk/en/publications/06eb0d5c-8aa3-4dca-bf28-5a0bf7f3ce6d
https://research.manchester.ac.uk/en/publications/06eb0d5c-8aa3-4dca-bf28-5a0bf7f3ce6d
Autor:
Cook, Audrey, Beesley, Sharon, O'Sullivan, Joe M, Birtle, Alison J, Thalmann, George, Graham, John D, Spears, Melissa R, Brock, Susannah, Srinivasan, Rajaguru, Protheroe, Andrew, Sydes, Matthew R, Laing, Robert, Cross, William, Matheson, David, Tsang, David, Parmar, Mahesh K B, Sundar, Santhanam, McKinna, Fiona, Parikh, Omi, Chowdhury, Simon, Robinson, Angus J, De Bono, Johann, Elliott, Tony, Mason, Malcolm D, Parker, Christopher C, Alzouebi, Mymoona, Gibbs, Stephanie, Dearnaley, David P, Millman, Robin, Russell, J Martin, Tolan, Shaun, Chakraborti, Prabir, Cathomas, Richard, Srihari, Narayanan, Clarke, Noel W, Peedell, Clive, James, Nicholas D, Staffurth, John, Gale, Joanna, Hetherington, John, Amos, Claire, Attard, Gerhardt, Hughes, Robert, Jones, Rob J, Ritchie, Alastair W S, McLaren, Duncan B, Wagstaff, John
Publikováno v:
James, N D, Sydes, M R, Clarke, N W, Mason, M D, Dearnaley, D P, Spears, M R, Ritchie, A W S, Parker, C C, Russell, J M, Attard, G, de Bono, J, Cross, W, Jones, R J, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, A J, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, J D, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, D B, O'Sullivan, J M, Parikh, O, Peedell, C, Protheroe, A, Robinson, A J, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, Parmar, M K B & STAMPEDE investigators 2016, ' Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial ', Lancet, vol. 387, no. 10024, pp. 1163–1177 . https://doi.org/10.1016/S0140-6736(15)01037-5
Lancet (London, England), vol. 387, no. 10024, pp. 1163-1177
Lancet, vol. 387, no. 10024, pp. 1163-1177
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; ... (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. Elsevier 10.1016/S0140-6736(15)01037-5
Lancet (London, England), vol. 387, no. 10024, pp. 1163-1177
Lancet, vol. 387, no. 10024, pp. 1163-1177
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; ... (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. Elsevier 10.1016/S0140-6736(15)01037-5
BACKGROUND: Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced
Autor:
Mason, Malcolm D., Clarke, Noel W., James, Nicholas D., Dearnaley, David P., Spears, Melissa R., Ritchie, Alastair W.S., Attard, Gerhardt, Cross, William, Jones, Rob J., Parker, Christopher C., Russell, J. Martin, Thalmann, George N., Schiavone, Francesca, Cassoly, Estelle, Matheson, David, Millman, Robin, Rentsch, Cyrill A., Barber, Jim, Gilson, Clare, Ibrahim, Azman, Logue, John, Lydon, Anna, Nikapota, Ashok D., O'Sullivan, Joe M., Porfiri, Emilio, Protheroe, Andrew, Srihari, Narayanan Nair, Tsang, David, Wagstaff, John, Wallace, Jan, Walmsley, Catherine, Parmar, Mahesh K.B., Sydes, Matthew R.
Publikováno v:
Mason, Malcolm D; Clarke, Noel W; James, Nicholas D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Attard, Gerhardt; Cross, William; Jones, Rob J; Parker, Christopher C; Russell, J Martin; Thalmann, George; Schiavone, Francesca; Cassoly, Estelle; Matheson, David; Millman, Robin; Rentsch, Cyrill A; Barber, Jim; Gilson, Clare; Ibrahim, Azman; ... (2017). Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of clinical oncology, 35(14), pp. 1530-1541. American Society of Clinical Oncology 10.1200/JCO.2016.69.0677
Purpose: Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally advanced or metastatic prostate